KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Cost of Revenue (2016 - 2025)

Historic Cost of Revenue for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $501.1 million.

  • West Pharmaceutical Services' Cost of Revenue rose 545.03% to $501.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.0 billion, marking a year-over-year increase of 397.95%. This contributed to the annual value of $2.0 billion for FY2025, which is 397.95% up from last year.
  • Latest data reveals that West Pharmaceutical Services reported Cost of Revenue of $501.1 million as of Q4 2025, which was up 545.03% from $510.3 million recorded in Q3 2025.
  • West Pharmaceutical Services' 5-year Cost of Revenue high stood at $510.3 million for Q3 2025, and its period low was $398.8 million during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $456.4 million (2023), whereas its average is $454.6 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Cost of Revenue soared by 2300.51% in 2021 and then grew by 14.34% in 2022.
  • West Pharmaceutical Services' Cost of Revenue (Quarter) stood at $430.2 million in 2021, then rose by 3.81% to $446.6 million in 2022, then increased by 1.61% to $453.8 million in 2023, then rose by 4.72% to $475.2 million in 2024, then rose by 5.45% to $501.1 million in 2025.
  • Its Cost of Revenue was $501.1 million in Q4 2025, compared to $510.3 million in Q3 2025 and $492.6 million in Q2 2025.